“…The hurdles to operate DASAs in aqueous solutions are most aggravating since they are native red/NIR-absorbing, negative photochromic compounds that would afford low scattering and deep penetration in tissue without incurring phototoxicity in biological applications . These properties are appealing for photopharmacology, which aims at controlling drug action on demand at selected locations using light, to enable precise responses and reduce unwanted side effects of treatments, or to manipulate specific cell types and neural circuits for investigational purposes. , Many photoswitchable bioactive molecules have been reported that offer high pharmacological specificity and potency for a diversity of targets, including ion channels, − G protein-coupled receptors, − protein–protein interactions, , and enzymes. − Most are based on aryl azo compounds, − which are difficult to isomerize using orange–red light without introducing substituents that often perturb the pharmacological properties of the original compound. − Photoswitching with continuous NIR light has been achieved in diazocines and using two-photon (2P) excitation of simple azobenzenes ,, in neurons, but the latter requires pulsed lasers and precision optics. , Thus, developing compounds that can be directly photoswitched in vivo with continuous-wave red or NIR light using portable devices (e.g., LEDs) remains an unmet need in basic and applied photopharmacology. They would enable noninvasive drug-based phototherapies and facilitate their translation to the clinic.…”